Macquarie initiated coverage of Privia Health (PRVA) with an Outperform rating and $25 price target Privia is an enduring leader aiding the transformation of the trillion-dollar healthcare industry to value-based care, the analyst tells investors in a research note. Privia has built a lasting business model that will allow it to sustain its growth momentum in the many years ahead, the firm says.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRVA:
- Privia Health price target raised to $28 from $27 at JPMorgan
- Privia Health price target raised to $27 from $24 at Truist
- Privia Health price target raised to $29 from $26 at Canaccord
- Privia Health price target raised to $21 from $19 at Barclays
- Privia Health Group Reports Strong Q3 2024 Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
